The best-known anti-IL-17 monoclonal antibodies are Secukinumab (SEC), Ixekizumab (IXE), and brodalumab (BROD), which are widely used in the treatment of IBD for psoriasis and ankylosing spondylitis. The gene discussed is IL17A; the disease is psoriasis.